A Double-Blind, Placebo-Controlled Randomized Study to Assess the Safety, Tolerability, and Pharmacokinetics of EVP-6124 in Participants With Schizophrenia on Stable Monotherapy With Selected Antipsychotics.

Trial Profile

A Double-Blind, Placebo-Controlled Randomized Study to Assess the Safety, Tolerability, and Pharmacokinetics of EVP-6124 in Participants With Schizophrenia on Stable Monotherapy With Selected Antipsychotics.

Completed
Phase of Trial: Phase I

Latest Information Update: 13 Jun 2014

At a glance

  • Drugs Encenicline (Primary)
  • Indications Schizophrenia
  • Focus Adverse reactions; Biomarker; Pharmacokinetics
  • Sponsors EnVivo Pharmaceuticals; FORUM Pharmaceuticals
  • Most Recent Events

    • 16 Mar 2012 Actual patient number changed from 20 to 21 as reported by ClinicalTrials.gov.
    • 16 Mar 2012 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health; NCT01556763).
    • 16 Mar 2012 Primary endpoints identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top